Carregant...

Proof-of-principle that a decoy virus protects oncolytic measles virus against neutralizing antibodies

BACKGROUND: Attenuated oncolytic measles virus (OMV) is a promising antitumor agent in early-phase clinical trials. However, pre-existing immunity against measles might be a hurdle for OMV therapy. METHODS: OMV was inactivated with short-wavelength ultraviolet light (UV-C). Loss of replication and o...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncolytic Virother
Autors principals: Xu, Chun, Goß, Annika Verena, Dorneburg, Carmen, Debatin, Klaus-Michael, Wei, Jiwu, Beltinger, Christian
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2018
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5933358/
https://ncbi.nlm.nih.gov/pubmed/29750140
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OV.S150637
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!